http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Fanpu Ji ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Jie Li ),( Biyao Zou ),( Hideki Fujii ),( Yee Hui Yeo ),( Fanpu Ji ),( Dong Hyun Lee ),( Yuemin Feng ),( Xiaoyu Xie ),( Wanhua Ren ),( Qiang Zhu ),( Mindie H. Nguyen ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: NAFLD is generally correlated with the obesity epidemic. Asia is a heterogeneous region with varying socioeconomic levels and obesity prevalence; therefore, our goal was to esti mate the prevalence of NAFLD in Asia through a meta-analytic approach. Methods: PubMed and EMBASE databases were searched from 1989 to 2017 for relevant studies reporting NAFLD prev alence in Asia. All studies were reviewed by three independent investigators. We used random-effects models to provide point estimates with 95% confidence interval (CI) of prevalence. Pub lication bias was assessed by Egger weighted regression Meth ods. Results: From the 2700 titles and abstracts reviewed, 195 pa pers from 13 countries met the inclusion criteria and included 1,753,168 subjects. The overall pooled prevalence for NAFLD in Asia was 31% (95% CI: 29-32). Individual country prevalence was shown in Table 1. In countries with more than 3 studies, the lowest prevalence was seen in Japan (24%, 95% CI: 21-28) and the highest in Iran (36%, 95%CI 31-41). Notably, pooled prevalence from studies with sample <1,000 subjects was much higher (34%, 95% CI: 31-38, 45 studies, n=23,857) than esti mate from larger studies (≥1,000 subjects) (30%, 95% CI: 28- 31, 150 studies, n=172,9311). By sub-regions within Asia (Table 2), there was significant regional differences (P<0.01) with the highest NAFLD prevalence seen in West Asia (33%, 95% CI: 28-39, 13 studies, n=32,142) and the lowest in Southeast Asia (24%, 95% CI: 15-33, 5 studies, n=3457). By country income levels, NAFLD prevalence was 30% (95% CI: 29-32, 89 studies, n=1,005,409) for high-income countries and 31% (95% CI: 29-33, 106 studies, n=747,759) for middle-income countries (P<0.63). Conclusions: Overall NAFLD prevalence in Asia is 31% similar to Western countries and by country-income levels within Asia but varies by some sub-regions or Asia with the highest preva lence in West Asia (33%).
-
Michael H. Le,David M. Le,Thomas C. Baez,Hansen Dang,Vy H. Nguyen,KeeSeok Lee,Christopher D. Stave,Takanori Ito,Yuankai Wu,Yee Hui Yeo,Fanpu Ji,Ramsey Cheung,Mindie H. Nguyen 대한간학회 2024 Clinical and Molecular Hepatology(대한간학회지) Vol.30 No.2
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events. Methods: We performed a systematic review and meta-analysis of cohort studies of adults with NAFLD to evaluate the pooled incidence of adverse events. Results: 19,406 articles were screened, 409 full-text articles reviewed, and 79 eligible studies (1,377,466 persons) were included. Mean age was 51.47 years and body mass index 28.90 kg/m2. Baseline comorbidities included metabolic syndrome (41.73%), cardiovascular disease (CVD) (16.83%), cirrhosis (21.97%), and nonalcoholic steatohepatitis (NASH) (58.85%). Incidence rate per 1,000 person-years for mortality included: all-cause (14.6), CVD-related (4.53), non-liver cancer-related (4.53), and liver-related (3.10). Incidence for liver-related events included overall (24.3), fibrosis progression (49.0), cirrhosis (10.9), liver transplant (12.0), and hepatocellular carcinoma (HCC) (3.39). Incidence for non-liver events included metabolic syndrome (25.4), hypertension (25.8), dyslipidemia (26.4), diabetes (19.0), CVD (24.77), renal impairment (30.3), depression/anxiety (29.1), and non-liver cancer (10.5). Biopsy-proven NASH had higher incidence of HCC (P=0.043) compared to non-NASH. Higher rates of CVD and mortality were observed in North America and Europe, hypertension and non-liver cancer in North America, and HCC in Western Pacific/Southeast Asia (P<0.05). No significant differences were observed by sex. Time-period analyses showed decreasing rates of cardiovascular and non-liver cancer mortality and increasing rates of decompensated cirrhosis (P<0.05). Conclusions: People with NAFLD have high incidence of liver and non-liver adverse clinical events, varying by NASH, geographic region, and time-period, but not sex.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
